Clinical trials: Early Alzheimer's Disease
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Alzheimer Disease, Early Onset
Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE
The purpose of this randomized, placebo-controlled phase 2b study is to prospectively evaluate AD04's potential as a disease-modifying drug in AD.
- Trial name
- NCT07107074
- Testing
- AD04
- Where
- 3 sites in Austria, Poland
- Volunteers
- 122 people
- Sponsor
- ADvantage Therapeutics
Early Alzheimer's Disease
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.
- Trial name
- APOLLOE4-LTE (NCT06304883)
- Testing
- Experimental: ALZ-801
- Where
- 41 sites in United States, Canada and 1 more
- Volunteers
- 163 people
- Sponsor
- Alzheon Inc.
Dementia
Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study
The investigators propose a stepwise screening approach. The first step involves rapid digital pre-screening of cognitive function through three components: the SCD-9 questionnaire to capture subjective cognitive complaints, a…
- Trial name
- NCT07284264
- Where
- 6 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Alzheimer's Disease (AD), Neurodegenerative Disease
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
The ADCHIP study (ST0067) is a non-interventional, monocentric, prospective study conducted by Amoneta Diagnostics and the Leenaards Memory Center (Lausanne, Switzerland).
- Conditions
- Alzheimer's Disease (AD), Neurodegenerative Disease, Dementia, Frontotemporal Dementia (FTD)
- Trial name
- ADCHIP (NCT07307872)
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease
- Trial name
- NCT05063539
- Testing
- LY3372689
- Where
- 69 sites in United States, Australia and 3 more
- Volunteers
- 327 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease, Healthy Participants
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with…
- Trial name
- NCT07780383
- Testing
- BMS-986446
- Where
- 6 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial)…
- Trial name
- NCT04468659
- Testing
- Lecanemab
- Where
- 107 sites in United States, Australia and 5 more
- Volunteers
- 1,400 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
Early Markers of Cognitive Change and Alzheimer s Disease
Background: The Baltimore Longitudinal Study of Aging (BLSA) is a long-term study of human aging. To see how the brain changes with age, researchers will study BLSA participants who are at least 60 years old.
- Trial name
- NCT01867346
- Where
- United States
- Volunteers
- 2,850 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Alzheimer Disease, Early Onset
Eardream Data Collection in Colombia Supported by ADDF
Data collection based on this study will allow us to collect neurophysiological and cognitive data collected from in-ear EEG recordings of the Autosomal dominant alzheimer's disease population in Colombia
- Trial name
- NCT05570370
- Testing
- This is an observational study
- Where
- Colombia
- Volunteers
- 120 people
- Sponsor
- Swiss Federal Institute of Technology
Mild Cognitive Impairment, Alzheimer Dementia
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
Muscle relaxation has been reported to be effective in alleviating anxiety and agitation symptoms in patients with dementia, but no studies have examined the effects of muscle relaxation therapy on cognitive function changes.
- Trial name
- NCT03507192
- Testing
- Muscle relaxation using full body massage machine
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Transcranial Direct Current Stimulation, Functional Magnetic Resonance Imaging
High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease
This completed randomized trial evaluated the clinical and neural effects of high-definition transcranial direct current stimulation (HD-tDCS) combined with computerized cognitive training in patients with Alzheimer's disease.
- Conditions
- Transcranial Direct Current Stimulation, Functional Magnetic Resonance Imaging, Early Alzheimer's Disease
- Trial name
- HD-tDCS (NCT04599764)
- Testing
- HD-tDCS, computer-based cognitive training, Control cognitive training
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Medical University
Alzheimer's Disease (AD)
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population.
- Trial name
- NCT05291234
- Testing
- ABBV-916
- Where
- 32 sites in United States
- Volunteers
- 106 people
- Sponsor
- AbbVie
Alzheimer's Disease
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes…
- Trial name
- ENVISION (NCT05310071)
- Testing
- Aducanumab
- Where
- 265 sites in United States, Australia and 14 more
- Volunteers
- 1,027 people
- Sponsor
- Biogen
Subjective Cognitive Decline, Alzheimer Disease
Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns
AHEAD is a prospective, longitudinal, risk-stratified single-arm interventional study enrolling 300 patients with Subjective Cognitive Decline (SCD) at IRCCS San Raffaele Hospital, Milan, Italy.
- Conditions
- Subjective Cognitive Decline, Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- AHEAD (NCT07652931)
- Testing
- High-frequency Transcranial Magnetic Stimulation (TMS), Digital Cognitive Training, Structured Physical Exercise
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS San Raffaele
Alzheimer Disease
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early…
- Trial name
- ALTITUDE-AD (NCT06335173)
- Testing
- sabirnetug
- Where
- 68 sites in United States, Canada and 3 more
- Volunteers
- 542 people
- Sponsor
- Acumen Pharmaceuticals
Alzheimer's Disease
Early Markers of Alzheimer's Disease: Structural and Functional Brain Changes
Background: Participants in the Baltimore Longitudinal Study of Aging are being studied to examine changes in brain structure and function over time, and to determine if these changes can predict the likelihood that an individual…
- Trial name
- NCT01867372
- Where
- 3 sites in United States
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Alzheimer's Disease
Memory and Insulin in Early Alzheimer's Disease
To determine which parts of the brain are involved in insulin-related memory improvement in early Alzheimer's disease and cognitively normal older adults.
- Trial name
- MAIN (NCT00581867)
- Testing
- Insulin Aspart
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Jeff Burns, MD
Alzheimer's Disease
Effects of Delivery Mode of Cognition Intervention in Early Alzheimer's Disease
The purpose of this study is to see if an intense two-week long cognitive training program helps the thinking ability of adults with very mild Alzheimer Disease.
- Trial name
- NCT00611312
- Testing
- Cognitive Training
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Kansas
Cognitive Decline, Mild, Alzheimer Disease
Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)
The goal of this placebo-controlled double-blind Phase 2 clinical trial is to test in people with early Alzheimer's Disease. The main questions it aims to answer are: Does treatment with fasudil, a ROCK-inhibitor, lead to…
- Trial name
- FEAD (NCT06362707)
- Testing
- Fasudil
- Where
- 6 sites in Norway
- Volunteers
- 200 people
- Sponsor
- Helse Stavanger HF